Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHYF) Equity Ratio (2017 - 2019)

Historic Equity Ratio for Innate Pharma (IPHYF) over the last 3 years, with Q4 2019 value amounting to 0.54.

  • Innate Pharma's Equity Ratio rose 4615.06% to 0.54 in Q4 2019 from the same period last year, while for Dec 2019 it was 0.54, marking a year-over-year increase of 4615.06%. This contributed to the annual value of 0.54 for FY2019, which is 4615.06% up from last year.
  • Innate Pharma's Equity Ratio amounted to 0.54 in Q4 2019, which was up 4615.06% from 0.37 recorded in Q4 2018.
  • In the past 5 years, Innate Pharma's Equity Ratio ranged from a high of 0.54 in Q4 2019 and a low of 0.34 during Q4 2017
  • Moreover, its 3-year median value for Equity Ratio was 0.37 (2018), whereas its average is 0.42.
  • As far as peak fluctuations go, Innate Pharma's Equity Ratio soared by 996.61% in 2018, and later soared by 4615.06% in 2019.
  • Innate Pharma's Equity Ratio (Quarter) stood at 0.34 in 2017, then grew by 9.97% to 0.37 in 2018, then skyrocketed by 46.15% to 0.54 in 2019.
  • Its Equity Ratio was 0.54 in Q4 2019, compared to 0.37 in Q4 2018 and 0.34 in Q4 2017.